Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Intellia Therapeutics (NTLA) to $45 from $50 and keeps an Overweight rating on the shares. The firm notes continued strong momentum for enrollment in Intellia’s phase 3 studies, boding well for commercial adoption. Wells also thinks the expansion of MAGNITUDE makes sense as it may support differentiated label and use, and note lack of impact to timeline.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
- Intellia Therapeutics Reports Q2 2025 Progress and Financials
- Intellia Therapeutics: Strategic Advancements and Promising Clinical Trials Justify Buy Rating
- Intellia Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
- Intellia Therapeutics price target lowered to $21 from $25 at RBC Capital